Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoto Tamura

Showing results (121-130 of 193) with videos related to

Pageof 20
Sort By:
The Journal of Rheumatology|March 3, 2015
Second-to-fourth Digit Ratio in Systemic Lupus ErythematosusKentaro Doe, Kazuhisa Nozawa, Takuya Hirai, et al.
Frontiers in Immunology|December 19, 2019
A Critical Role for Mucosal-Associated Invariant T Cells as Regulators and Therapeutic Targets in Systemic Lupus ErythematosusGoh Murayama, Asako Chiba, Hitoshi Suzuki, et al.
The Journal of Rheumatology|July 3, 2016
Involvement of Mucosal-associated Invariant T cells in Ankylosing SpondylitisEri Hayashi, Asako Chiba, Kurisu Tada, et al.
BMC Immunology|August 24, 2017
JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulationKeigo Ikeda, Kunihiro Hayakawa, Maki Fujishiro, et al.
Modern Rheumatology|December 7, 2016
Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in JapanTsuneyo Mimori, Masayoshi Harigai, Tatsuya Atsumi, et al.
Modern Rheumatology|February 22, 2012
Recent trends in use of nonbiologic DMARDs and evaluation of their continuation rates in single and dual combination therapies in rheumatoid arthritis patients in JapanMichihiro Ogasawara, Michiaki Kageyama, Makio Kusaoi, et al.
Modern Rheumatology|April 4, 2018
Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance studyTsuneyo Mimori, Masayoshi Harigai, Tatsuya Atsumi, et al.
Clinical and Experimental Rheumatology|October 23, 2013
Can routine clinical measures predict ultrasound-determined synovitis and remission in rheumatoid arthritis patients?Takuya Nemoto, Michihiro Ogasawara, Yuko Matsuki, et al.
Clinical Rheumatology|October 27, 2016
The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical studyTakuya Hirai, Keigo Ikeda, Maki Fujishiro, et al.
Frontiers in Immunology|December 6, 2021
Anti-TLR7 Antibody Protects Against Lupus Nephritis in NZBWF1 Mice by Targeting B Cells and Patrolling MonocytesYusuke Murakami, Ryutaro Fukui, Reika Tanaka, et al.
Pageof 20

Showing results (121-130 of 193) with videos related to

Sort By:
Pageof 20
The Journal of Rheumatology|March 3, 2015
Second-to-fourth Digit Ratio in Systemic Lupus ErythematosusKentaro Doe, Kazuhisa Nozawa, Takuya Hirai, et al.
Frontiers in Immunology|December 19, 2019
A Critical Role for Mucosal-Associated Invariant T Cells as Regulators and Therapeutic Targets in Systemic Lupus ErythematosusGoh Murayama, Asako Chiba, Hitoshi Suzuki, et al.
The Journal of Rheumatology|July 3, 2016
Involvement of Mucosal-associated Invariant T cells in Ankylosing SpondylitisEri Hayashi, Asako Chiba, Kurisu Tada, et al.
BMC Immunology|August 24, 2017
JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulationKeigo Ikeda, Kunihiro Hayakawa, Maki Fujishiro, et al.
Modern Rheumatology|December 7, 2016
Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in JapanTsuneyo Mimori, Masayoshi Harigai, Tatsuya Atsumi, et al.
Modern Rheumatology|February 22, 2012
Recent trends in use of nonbiologic DMARDs and evaluation of their continuation rates in single and dual combination therapies in rheumatoid arthritis patients in JapanMichihiro Ogasawara, Michiaki Kageyama, Makio Kusaoi, et al.
Modern Rheumatology|April 4, 2018
Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance studyTsuneyo Mimori, Masayoshi Harigai, Tatsuya Atsumi, et al.
Clinical and Experimental Rheumatology|October 23, 2013
Can routine clinical measures predict ultrasound-determined synovitis and remission in rheumatoid arthritis patients?Takuya Nemoto, Michihiro Ogasawara, Yuko Matsuki, et al.
Clinical Rheumatology|October 27, 2016
The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical studyTakuya Hirai, Keigo Ikeda, Maki Fujishiro, et al.
Frontiers in Immunology|December 6, 2021
Anti-TLR7 Antibody Protects Against Lupus Nephritis in NZBWF1 Mice by Targeting B Cells and Patrolling MonocytesYusuke Murakami, Ryutaro Fukui, Reika Tanaka, et al.
Pageof 20